Donor spontaneous intracerebral hemorrhage is associated with systemic activation of matrix metalloproteinase-2 and matrix metalloproteinase-9 and subsequent development of coronary vasculopathy in the heart transplant recipient

Circulation

Volumn 108, Issue 14, 2003, Pages 1724-1728

  Yamani, Mohamad H ^a   Starling, Randall C ^a   Cook, Daniel J ^a   Tuzcu, E Murat ^a   Abdo, Ashraf ^a   Paul, Philip ^a   Powell, Kimerly ^a   Ratliff, Norman B ^a   Yu, Yang ^a   McCarthy, Patrick M ^a   Young, James B ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Hemorrhage; Metalloproteinases; Transplantation

Indexed keywords

GELATINASE A; GELATINASE B; MESSENGER RNA;

ALLOGRAFT; ARTICLE; BRAIN HEMORRHAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DONOR; ENZYME ACTIVATION; ENZYME ANALYSIS; EVALUATION; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HEART TRANSPLANTATION; HUMAN; HYPOTHESIS; INTRAVASCULAR ULTRASOUND; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RISK ASSESSMENT; RNA ANALYSIS; SPLEEN LYMPHOCYTE;

ADULT; CEREBRAL HEMORRHAGE; CORONARY DISEASE; CORONARY VESSELS; ENZYME ACTIVATION; FEMALE; HEART TRANSPLANTATION; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; RNA, MESSENGER; TISSUE DONORS;

EID: 0141885285     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000087604.27270.5B     Document Type: Article

References (23)

1. Tsai F, Marelli D, Bresson J, et al. Use of hearts transplanted from donors with atraumatic intracranial bleed. J Heart Lung Transplant. 2002;21:623-628.
2. Baroldi G, Pasquale G, Silver M, et al. Type and extent of myocardial injury related to brain damage and its significance in heart transplantation: a morphometric study. J Heart Lung Transplant. 1997;16:994-1000.
3. Ries C, Petrides PE. Cytokine regulation of matrix metalloproteinase activity and regulatory dysfunction in disease. Biol Chem. 1995;376:345-355.
4. Mun-Bryce S, Rosenberg GA. Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab. 1998;18:1163-1172.
5. Rosenberg GA, Navratil M. Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat. Neurology. 1997;48:921-926.
6. Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003;107:598-603.
7. Zachary A, Teresi G. Isolation of lymphocyte from lymph nodes and spleen. In: Lefor W, ed. ASHI Laboratory Manual. 2nd ed. 1990;32-37.
8. Fahmy NM, Yamani MH, Starling RC, et al. Chemokine and chemokine receptor gene expression indicates acute rejection of human cardiac transplants. Transplantation. 2003;75:72-78.
9. -CT method. Methods. 2001;25:402-408.
10. Kapadia SR, Nissen S, Ziada K, et al. Development of transplantation vasculopathy and progression of donor-transmitted atherosclerosis: comparison by serial intravascular ultrasound imaging. Circulation. 1998;98:2672T-2678T.
11. Otsu N. A threshold selection method from gray-level histograms. IEEE Trans Syst Man Cybern. 1979;9:62-66.
12. Bishay ES, Cook DJ, El Fettouh H, et al. The impact of HLA sensitization and donor cause of death in heart transplantation. Transplantation. 2000;70:220-222.
13. Yamani MH, Haji SA, Starling RC, et al. Myocardial ischemic-fibrotic injury following human heart transplantation is associated with increased progression of vasculopathy, decreased cellular rejection, and poor long-term outcome. J Am Coll Cardiol. 2002;39:970-977.
14. Yamani MH, Tuzcu EM, Starling RC, et al. Myocardial ischemic injury following heart transplantation is associated with upregulation of vitronectin receptor (αvβ3), activation of the matrix metalloproteinase induction system, and subsequent development of coronary vasculopathy. Circulation. 2002;105:1995-1961.
15. Spinale FG, Coker ML, Heung LJ, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation. 2000;102:1944-1949.
16. Romanic AM, Harrison SM, Bao W, et al. Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. Cardiovasc Res. 2002;54:549-558.
17. Wills A, Thompson MM, Crowther M, et al. Pathogenesis of abdominal aortic aneurysms-cellular and biochemical mechanisms. Eur J Vasc Endovasc Surg. 1996;12:391-400.
18. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90:251-262.
19. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke. 1998;29:1020-1030.
20. Lapchak PA, Chapman DF, Zifin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thrombolytic stroke. Stroke. 2000;31:3034-3040.
21. Yakubenko VP, Lobb RR, Plow E, et al. Differential induction of gelatinase B (MMP-9) and gelatinase A (MMP-2) in T lymphocytes upon α4β1-mediated adhesion to VCAM-1 and the CS-1 peptide of fibronectin. Exp Cell Res. 2000;260:73-84.
22. Khan KM, Falcone DJ, Kraemer R. Nerve growth factor activation of Erk-1 and Erk-2 induces matrix metalloproteinase-9 expression in vascular smooth muscle cells. J Bio Chem. 2002;277:2353-2359.
23. Tsukioka K, Suzuki J, Kawauchi M, et al. Expression of membrane-type 1 matrix metalloproteinase in coronary vessels of allotransplanted primate hearts. J Heart Lung Transplant. 2000;19:1193-1198.